A detailed history of E Fund Management Co., Ltd. transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 48,097 shares of IRWD stock, worth $312,149. This represents 0.03% of its overall portfolio holdings.

Number of Shares
48,097
Previous 37,687 27.62%
Holding current value
$312,149
Previous $431,000 3.02%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$8.32 - $15.45 $86,611 - $160,834
10,410 Added 27.62%
48,097 $418,000
Q4 2023

Feb 06, 2024

SELL
$8.79 - $11.51 $63,367 - $82,975
-7,209 Reduced 16.06%
37,687 $431,000
Q3 2023

Nov 13, 2023

BUY
$8.25 - $11.35 $48,732 - $67,044
5,907 Added 15.15%
44,896 $432,000
Q2 2023

Aug 11, 2023

BUY
$10.1 - $11.6 $37,067 - $42,572
3,670 Added 10.39%
38,989 $415,000
Q1 2023

May 11, 2023

SELL
$10.37 - $12.56 $3,795 - $4,596
-366 Reduced 1.03%
35,319 $372,000
Q4 2022

Feb 14, 2023

SELL
$9.9 - $12.43 $75,428 - $94,704
-7,619 Reduced 17.59%
35,685 $442,000
Q3 2022

Nov 14, 2022

BUY
$10.14 - $12.38 $61,235 - $74,762
6,039 Added 16.21%
43,304 $449,000
Q2 2022

Aug 15, 2022

BUY
$11.05 - $12.72 $157,782 - $181,628
14,279 Added 62.12%
37,265 $430,000
Q1 2022

May 12, 2022

BUY
$10.61 - $12.88 $78,344 - $95,105
7,384 Added 47.33%
22,986 $289,000
Q4 2021

Feb 11, 2022

BUY
$10.86 - $13.95 $15,985 - $20,534
1,472 Added 10.42%
15,602 $182,000
Q3 2021

Nov 12, 2021

BUY
$11.92 - $13.92 $22,361 - $26,113
1,876 Added 15.31%
14,130 $185,000
Q1 2021

May 12, 2021

BUY
$9.04 - $11.86 $110,776 - $145,332
12,254 New
12,254 $136,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $994M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.